Bolt Biotherapeutics Announces Changes to its Board of Directors
September 04, 2024 16:05 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024 16:05 ET
|
Bolt Biotherapeutics, Inc.
Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society...
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
May 14, 2024 16:05 ET
|
Bolt Biotherapeutics, Inc.
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further...
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
December 05, 2023 07:00 ET
|
Bolt Biotherapeutics, Inc.
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersPoster detailing trial design...